Tag: beta-adrenergic blockers

‘Quadpill’ Bests Monotherapy for Initial BP Lowering: QUARTET

A “quadpill” containing quarter doses of four blood pressure (BP)-lowering medications was more effective than monotherapy for initial treatment of hypertension, with similar tolerability, in...

Oral Contraceptives, Sans Beta Blockade, Raise SCD Risk in LQTS

Contemporary oral contraceptives (OC) in general don’t seem to worsen the risk for sudden cardiac death (SCD) in women with congenital long-QT syndrome (LQTS), but...

HF Med Undertreatment Due to Older Age Common, Flouts Evidence

Advanced age by itself can be a reason physicians hold back on prescribing mainstay medications, or not uptitrate them per guidelines, to their older patients...

Mavacamten Boosts Quality of Life in Hypertrophic Cardiomyopathy

Of patients with symptomatic, obstructive hypertrophic cardiomyopathy treated with the investigational oral agent mavacamten, more than twice as many, compared with placebo, had a very...

JACC Expert Consensus Decision Pathways for HF Treatment

A newly updated expert consensus from the American College of Cardiology (ACC) for management of heart failure with reduced ejection fraction (HFrEF) includes several new...

Digoxin a ‘Viable Alternative’ in AF With HF: RATE-AF Published

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker...

Beta-Blocker May Improve Melanoma Treatment Response

Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with...

SAMSON Pins Most Muscle Pain With Statins on the Nocebo Effect

A novel randomized trial taking on a vexing issue around one of the world’s most commonly prescribed medications has concluded that frequently intolerable statin side...

New ‘Myotropic’ Class Has Modest HFrEF Benefit

Omecamtiv mecarbil, a member of the novel myotropic drug class that improves cardiac performance, safely produced a significant but modest improvement in heart failure events...

Vericiguat Benefits Even With High Adherence to HFrEF Meds

Vericiguat (Merck/Bayer), among the latest drugs to gain cred in heart failure (HF) with reduced ejection fraction (HFrEF), significantly benefits patients who are highly adherent...

Study Questions Routine Long-term Beta-Blocker Post MI

Current American and European guidelines recommending long-term beta-blocker therapy following an acute MI appear to be obsolete in the modern reperfusion era, suggests an analysis...

RATE-AF Trial Boosts Digoxin for Rate Control in Permanent AF

Digoxin now deserves to be considered first-line therapy for long-term heart rate control in older patients with permanent atrial fibrillation and symptoms of heart failure,...

Trimetazidine Fizzles for Post-PCI Angina

Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a non–ST-elevated myocardial infarction (MI),...

Empagliflozin’s HFrEF Benefit Solidifies Class Effects

The SGLT2 inhibitor drug class solidified its role as a major, new treatment for patients who have heart failure with reduced ejection fraction and no...

Nine Antihypertensive Drugs Associated With Reduced Risk for Depression

The risk of depression is elevated in patients with cardiovascular diseases, but several specific antihypertensive therapies are associated with a reduced risk, and none appear...

Prior Beta Blockers Predict Extra HF Burden in Women With ACS

Beta blockers taken for hypertension may predispose women to worse outcomes, compared with men, when they later present with acute coronary syndromes (ACS), a registry...